A method of diagnosis of colorectal cancer in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting differential expression of two or more proteins in the diagnostic sample, compared with a control, normal human sample, the proteins being selected from the following in which an increased concentration of protein in the diagnostic sample is detected:heat shock protein HSP90-beta (SwissProt Acc. No. P08238)transforming growth factor-beta induced protein IG-H3 (SwissProt Acc. No. Ql 5582)suppressor of G2 allele of SKP1 homolog (isoform 2) (SwissProt Acc. No. Q9Y2Z0-2)hypothetical protein (part of URG4) (SwissProt Acc. No. Q9NWR7)calponin-2 (SwissProt Acc. No. Q99439)phosphoglycerate mutase 1 (SwissProt Acc. No. P1 8669)serpin Cl protein (SwissProt Acc. No. P01008) orhaptoglobin precursor (SwissProt Acc. No. P00738)and/or from the following in which a decreased concentration of protein in the diagnostic sample is detected:serotransferrin (SwissProt Acc. No. P02787)26S proteasome subunit p40.5 (Swiss Prot Acc. No. Q9UNM7)aldo-keto reductase family 1 member B10 (SwissProt Acc. No. 060218)fructosamine-3-kinase (SwissProt Acc. No. Q9H479)peripherin (SwissProt Acc. No. P41219)alpha-2-macroglobulin (SwissProt Acc. No. P01023)serpin Cl protein (SwissProt Acc. No. P01008) orapolipoprotein A IV (SwissProt Acc. No. P06727).
